000283154 001__ 283154
000283154 005__ 20260109155332.0
000283154 0247_ $$2doi$$a10.1002/alz70856_105476
000283154 0247_ $$2ISSN$$a1552-5260
000283154 0247_ $$2ISSN$$a1552-5279
000283154 037__ $$aDZNE-2026-00050
000283154 041__ $$aEnglish
000283154 082__ $$a610
000283154 1001_ $$aSteward, Anna$$b0
000283154 1112_ $$aAlzheimer’s Association International Conference$$cToronto$$d2025-07-27 - 2025-07-31$$gAAIC 25$$wCanada
000283154 245__ $$aApoE4 accelerates p ‐tau driven tau aggregation and spread in Alzheimer's Disease in a allele‐dose dependent manner
000283154 260__ $$c2025
000283154 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1767970391_5997
000283154 3367_ $$033$$2EndNote$$aConference Paper
000283154 3367_ $$2BibTeX$$aINPROCEEDINGS
000283154 3367_ $$2DRIVER$$aconferenceObject
000283154 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$mjournal
000283154 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000283154 3367_ $$2ORCID$$aOTHER
000283154 520__ $$aBackground: Understanding factors influencing Alzheimer's disease (AD) progression is crucial for optimising treatment timing and targets. A major genetic risk factor, the Apolipoprotein E ε4 allele (ApoE4), is associated with earlier tau pathology accumulation and spread at lower amyloid-beta (Aβ) levels (Steward, JAMA Neurol, 2023). However, the mechanisms underlying this association remain unclear (Figure 1A). Therefore, we assessed how ApoE4 accelerates Aβ-related tau aggregation. Specifically, we investigated whether ApoE4 promotes Aβ-driven secretion of phospho tau (p-tau) or ptau dependent tau aggregation, and determined whether ApoE4 promotes tau pathology in an allele dose-dependent manner. Method: We analysed data from APOE-genotyped AD-spectrum participants in the ADNI (n = 201) and A4 cohorts (n = 200), integrating cross-sectional fluid biomarker measures (plasma ptau217, CSF ptau181) and longitudinal Flortaucipir tau-PET and Florbetaben/Florbetapir amyloid-PET. Using linear regression, we assessed whether the interaction between amyloid-PET and ApoE4 allele dosage influences plasma ptau217, and replicated this analysis with CSF ptau181 in an ADNI subset (n = 115). Secondly, to investigate whether ApoE4 enhances tau fibrilisation and spread, we calculated annual tau-PET SUVR accumulation rates across a connectivity-based tau spreading stages, using our prior methodology (e.g. Franzmeier, Sci Adv, 2020). Linear regressions tested the interaction between ptau217 (or CSF ptau181) and ApoE4 allele count on connectivity-mediated tau-PET accumulation in four connectivity stages that capture progressive tau spread. Result: ApoE4 allele dosage did not moderate the relationship between amyloid-PET and plasma ptau217 in either sample (Figure 1B, ADNI: β=0.13, p = 0.32; A4: β=-0.20, p = 0.17) nor between amyloid-PET and CSF ptau181 in ADNI subsample (Figure 1B, b=-.16, p = 0.42). However, a significant ApoE4 allele dose effect was observed in moderating the relationship between plasma ptau217 and tau-PET accumulation across connectivity stages independent of amyloid burden (Figure 1C, ADNI: Q1–4 mean β=0.44, Q1-4 p <0.001; A4: Q1-4 mean β = 0.56, Q1,2,4 p <0.001, Q3 p <0.05), with the strongest effect in individuals carrying two ApoE4 alleles. Conclusion: ApoE4 exerts an allele dose-dependent effect on ptau induced tau aggregation, driving accelerated tau spreading at lower Aβ levels. This suggests that attenuating soluble ptau increases in ApoE4 carriers may mitigate downstream tau fibrilisation and delay dementia onset, highlighting the potential of personalised therapeutic approaches.
000283154 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000283154 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000283154 650_7 $$2NLM Chemicals$$atau Proteins
000283154 650_7 $$2NLM Chemicals$$aBiomarkers
000283154 650_7 $$2NLM Chemicals$$aApolipoprotein E4
000283154 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000283154 650_7 $$2NLM Chemicals$$aMAPT protein, human
000283154 650_2 $$2MeSH$$aHumans
000283154 650_2 $$2MeSH$$atau Proteins: cerebrospinal fluid
000283154 650_2 $$2MeSH$$atau Proteins: metabolism
000283154 650_2 $$2MeSH$$atau Proteins: blood
000283154 650_2 $$2MeSH$$aAlzheimer Disease: genetics
000283154 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000283154 650_2 $$2MeSH$$aAlzheimer Disease: cerebrospinal fluid
000283154 650_2 $$2MeSH$$aAlzheimer Disease: metabolism
000283154 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000283154 650_2 $$2MeSH$$aBiomarkers: blood
000283154 650_2 $$2MeSH$$aFemale
000283154 650_2 $$2MeSH$$aMale
000283154 650_2 $$2MeSH$$aApolipoprotein E4: genetics
000283154 650_2 $$2MeSH$$aAmyloid beta-Peptides: metabolism
000283154 650_2 $$2MeSH$$aAmyloid beta-Peptides: cerebrospinal fluid
000283154 650_2 $$2MeSH$$aAged
000283154 650_2 $$2MeSH$$aPositron-Emission Tomography
000283154 650_2 $$2MeSH$$aAged, 80 and over
000283154 650_2 $$2MeSH$$aCross-Sectional Studies
000283154 650_2 $$2MeSH$$aAlleles
000283154 650_2 $$2MeSH$$aBrain: diagnostic imaging
000283154 650_2 $$2MeSH$$aBrain: metabolism
000283154 7001_ $$aDewenter, Anna$$b1
000283154 7001_ $$aRoemer-Cassiano, Sebastian$$b2
000283154 7001_ $$aBiel, Davina$$b3
000283154 7001_ $$aZhu, Zeyu$$b4
000283154 7001_ $$aFrontzkowski, Lukas$$b5
000283154 7001_ $$aHirsch, Fabian$$b6
000283154 7001_ $$aKlonowksi, Madleen$$b7
000283154 7001_ $$0P:(DE-2719)9001652$$aGnoerich, Johannes$$b8$$udzne
000283154 7001_ $$aDehsarvi, Amir$$b9
000283154 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b10$$udzne
000283154 7001_ $$aFranzmeier, Nicolai$$b11
000283154 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz70856_105476$$gVol. 21, no. S2, p. e105476$$nS2$$pe105476$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000283154 8564_ $$uhttps://pub.dzne.de/record/283154/files/DZNE-2026-00050.pdf$$yRestricted
000283154 8564_ $$uhttps://pub.dzne.de/record/283154/files/DZNE-2026-00050.pdf?subformat=pdfa$$xpdfa$$yRestricted
000283154 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001652$$aExternal Institute$$b8$$kExtern
000283154 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001539$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000283154 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000283154 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283154 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283154 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283154 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283154 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283154 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283154 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283154 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283154 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283154 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283154 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x0
000283154 980__ $$aabstract
000283154 980__ $$aEDITORS
000283154 980__ $$aVDBINPRINT
000283154 980__ $$ajournal
000283154 980__ $$aI:(DE-2719)1110007
000283154 980__ $$aUNRESTRICTED